Most Read Articles
Tristan Manalac, 11 Jul 2018
Gestational exposure to grain products fortified with folic acid appears to be linked to a lower risk of psychosis in offspring, according to a recent study.
Pearl Toh, 10 Jul 2018
A dual-hormone artificial pancreas (DAP) with a rapid delivery of insulin and pramlintide in a fixed ratio improves glycaemic control and reduces glucose variability in adults with type 1 diabetes (T1D) compared with first-generation artificial pancreas delivering insulin alone, according to a study presented at ADA 2018.
4 days ago
Chocolate consumption is not associated with risk of coronary heart disease (CHD), stroke or both combined in postmenopausal women free of pre-existing major chronic disease, a study suggests.
Pearl Toh, 5 days ago
More intensive lowering of LDL-C levels was associated with a progressively greater survival benefit than less intensive approach, when the baseline LDL-C levels were ≥100 mg/dL, reveals a meta-analysis of 34 randomized trials.

Fidaxomicin therapy most effective during first episode of C. difficile infection

14 Jan 2018

Patients with a first episode of Clostridium difficile infection (CDI) are likely to respond to treatment with fidaxomicin with no recurrences, a recent study has shown. On the other hand, those with prior CDI episodes are less likely to respond, especially with >1 prior episode, and more likely to recur, which suggests a greater clinical benefit of fidaxomicin earlier in the course of CDI.

There were 81 patients (median age 55.9 years; 53 percent female; 26 percent with inflammatory bowel disease) included in the study, of which 90 percent responded to fidaxomicin therapy. Prior CDI episodes were fewer (p=0.01) in responders (median, 1; range, 0‒8) vs nonresponders (median, 2.5; range, 1‒8). Response was 100 percent after a first CDI episode, 96 percent after one prior episode, and 82 percent after two or more (p=0.02).

There was a 19-percent recurrence rate. Patients who did not recur had fewer prior episodes of CDI (median 1; range 0‒6) than those with a recurrence (median, 2; range, 1‒8; p=0.005). Recurrence was 0 percent after a first episode, 23 percent after one prior episode, and 29 percent after two or more (p=0.005).

All patients with inflammatory bowel disease, as a response, either improved their symptoms or had a negative C. difficile test. Recurrence occurred in 19 percent.

The investigators included all CDI cases treated with fidaxomicin at three referral centres over a 4-year period. The definition of ‘response’ was resolution of diarrhoea, and ‘recurrence’ was defined by CDI recurrence within 8 weeks of the end of treatment.

“Fidaxomicin is a new antibiotic used to treat CDI,” according to the investigators. 

Digital Edition
Asia's trusted medical magazine for healthcare professionals. Get your MIMS Doctor - Malaysia digital copy today!
Sign In To Download
Editor's Recommendations
Most Read Articles
Tristan Manalac, 11 Jul 2018
Gestational exposure to grain products fortified with folic acid appears to be linked to a lower risk of psychosis in offspring, according to a recent study.
Pearl Toh, 10 Jul 2018
A dual-hormone artificial pancreas (DAP) with a rapid delivery of insulin and pramlintide in a fixed ratio improves glycaemic control and reduces glucose variability in adults with type 1 diabetes (T1D) compared with first-generation artificial pancreas delivering insulin alone, according to a study presented at ADA 2018.
4 days ago
Chocolate consumption is not associated with risk of coronary heart disease (CHD), stroke or both combined in postmenopausal women free of pre-existing major chronic disease, a study suggests.
Pearl Toh, 5 days ago
More intensive lowering of LDL-C levels was associated with a progressively greater survival benefit than less intensive approach, when the baseline LDL-C levels were ≥100 mg/dL, reveals a meta-analysis of 34 randomized trials.